Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06361316
NA

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Sponsor: Kuirong Jiang

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.

Official title: Efficacy and Safety of Irinotecan Liposome Injection Combined With Oxaliplatin and Tegafur (NASOX) in Adjuvant Chemotherapy for Pancreatic Cancer

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

53

Start Date

2024-04-08

Completion Date

2028-07-31

Last Updated

2024-04-11

Healthy Volunteers

No

Interventions

DRUG

Irinotecan liposome injection

Postoperative adjuvant therapy

Locations (1)

FirstNanjingMU

Nanjing, Jiangsu, China